- Current report filing (8-K)
January 14 2010 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported):
January 14, 2010 (January 8, 2010)
|
|
|
|
CHINA BIOLOGIC PRODUCTS, INC.
|
(Exact name of registrant as
specified in its charter)
|
|
|
|
Delaware
|
|
|
001-34566
|
|
|
75-2308816
|
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File No.)
|
(IRS Employer ID No.)
|
|
|
|
|
|
|
No. 14 East Hushan Road,
|
|
|
Tai'an City, Shandong
|
|
|
People's Republic of China
|
|
271000
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
|
86-538 -620-2306
|
|
Registrant's telephone number, including area code
|
|
|
(Former name or former address, if
changed since last report)
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
£
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item 5.02.
Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On January 8, 2010, Dr. Jie Gan resigned from the board of
directors of China Biologic Products, Inc. (the "Company"), effective
immediately. Dr. Gans resignation was not because of any disagreement with the
Company on any matter relating to the Companys operations, policies or
practices.
The board of directors of the Company is currently reviewing
candidates to fill the vacancy caused by Dr. Gans departure and will announce
the appointment of a suitable candidate as soon as such determination is made.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 14, 2010
|
CHINA BIOLOGIC
PRODUCTS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Chao Ming Zhao
|
|
|
Chao
Ming Zhao
|
|
|
Chief Executive Officer
|
|
|
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024